Shots:
- Zonsen PepLib Biotech has entered into a worldwide R&D and license agreement with Eli Lilly to jointly advance peptide-based drug candidates using PepLib’s robust & diverse peptide libraries & discovery platforms
- As per the deal, PepLib will screen & identify optimal peptide molecules using its in-house platform, while Lilly will oversee IND-enabling activities, clinical development, & commercialization
- In return, PepLib will receive an upfront & near-term payment, with additional development, regulatory, & sales milestone payments, & tiered royalties on future global net sales
Ref: Businesswire | Image: PepLib & Eli Lilly | Press Release
Related News: Zonsen PepLib Biotech Grants Novartis Global License for Radioligand Therapy Asset with $50M Upfront
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
